In a report released today, Kevin Dede from H.C. Wainwright reiterated a Buy rating on Biotricity (BTCY – Research Report), with a price target of $2.00. The company’s shares closed yesterday at $1.03.
Dede covers the Technology sector, focusing on stocks such as Kopin, Canaan, and HIVE Blockchain Technologies. According to TipRanks, Dede has an average return of -11.7% and a 27.83% success rate on recommended stocks.
Biotricity has an analyst consensus of Moderate Buy, with a price target consensus of $2.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $5.30 and a one-year low of $0.75. Currently, Biotricity has an average volume of 205.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biotricity, Inc. engages in the provision of biometric data monitoring solutions. The firm offers the Bioflux, a single-unit mobile cardiac telemetry device. It also develops Biolife, which is intended for chronic disease prevention. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.
Read More on BTCY:
